Biocon Biologics signs settlement and license agreement with Janssen Biotech and Johnson & Johnson to commercialize Bmab 1200, a biosimilar to Stelara, in the US once approved by the USFDA. The therapy is expected to launch in February 2025.
Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News